Merck Uses Phosphoproteomics to Identify Potential Biomarkers for Cancer Drug Development
August 06, 2010
Merck Uses Phosphoproteomics to Identify Potential Biomarkers for Cancer Drug Development
In a study, Merck scientists identified 71 phosphoproteins that could be useful biomarkers for predicting the efficacy of drugs targeting a cancer-linked signaling pathway.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Researchers ID Gastric Cancer Biomarker Aimed for Use in DTC Tests in US, China
May 6, 2011 / ProteoMonitor - Magnetic Biosensor Could Enable Simultaneous Monitoring of Thousands of Protein-Ligand Bindings
May 6, 2011 / ProteoMonitor - NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
April 22, 2011 / ProteoMonitor - NextGen Launches Protein Biomarker Discovery Panel; Aims to Take Market Share from RBM
March 18, 2011 / ProteoMonitor - Biodesix Raises $7.1M in Series C Financing Round
November 12, 2010 / ProteoMonitor